BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12601543)

  • 1. Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
    Shimoyama S; Aoki F; Shimizu N; Tatsutomi Y; Mafune K; Kaminishi M
    Int J Clin Oncol; 2003 Feb; 8(1):49-52. PubMed ID: 12601543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].
    Shimoyama S; Imamura K; Katayama A; Hiki N; Shimizu N; Yamaguchi H; Mafune K; Motoi T; Oohashi K; Kaminishi M
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):929-32. PubMed ID: 15222115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
    Shirao K; Shimada Y; Kondo H; Saito D; Yamao T; Ono H; Yokoyama T; Fukuda H; Oka M; Watanabe Y; Ohtsu A; Boku N; Fujii T; Oda Y; Muro K; Yoshida S
    J Clin Oncol; 1997 Mar; 15(3):921-7. PubMed ID: 9060529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.
    Lim WT; Lim ST; Wong NS; Koo WH
    J Chemother; 2003 Aug; 15(4):400-5. PubMed ID: 12962370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
    Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
    Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
    Sakamoto T; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Machida N; Todaka A; Tomita H; Tsushima T; Taniguchi H; Hamauchi S
    Int J Clin Oncol; 2010 Jun; 15(3):287-93. PubMed ID: 20217447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
    Ueda S; Hironaka S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
    Gastric Cancer; 2006; 9(3):203-7. PubMed ID: 16952039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study.
    Mitachi Y; Sakata Y; Ohtsu A; Hyodo I; Katsu K; Sairenji M; Saitoh S; Suwa T; Sato T; Miyata Y
    Gastric Cancer; 2002; 5(3):160-7. PubMed ID: 12378343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
    Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
    Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.
    Katsube T; Ogawa K; Ichikawa W; Fujii M; Tokunaga A; Takagi Y; Kochi M; Hayashi K; Kubota T; Aiba K; Arai K; Terashima M; Kitajima M
    Anticancer Drugs; 2007 Jun; 18(5):605-10. PubMed ID: 17414630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy of low-dose CDDP and CPT-11 therapy as second- or third-line chemotherapy for advanced and recurrent gastric cancer].
    Ito S; Takagawa R; Minami Y; Watanabe J; Morita T; Mogaki M; Masui H
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1107-11. PubMed ID: 25248893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
    Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
    Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.
    Yamao T; Ohta K; Ohyama S; Ishihara S; Chin K; Maruyama M; Takahashi T; Nakajima T
    Jpn J Clin Oncol; 2004 May; 34(5):255-61. PubMed ID: 15231860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of advanced gastric cancer treated with neoadjuvant chemotherapy of low-dose CPT-11 + CDDP].
    Tadatomo H; Suzuki K; Ando M; Yamashita S; Tanaka K; Maruyama S; Harada Y; Ohnuma S; Sakaniwa N; Koyanagi Y
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):821-4. PubMed ID: 11432351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
    Satoh S; Kawashima K; Matsumoto S; Hasegawa S; Okabe H; Nomura A; Yoshibayashi H; Watanabe G; Nagayama S; Fukushima M; Sakai Y
    Chemotherapy; 2007; 53(3):226-32. PubMed ID: 17356271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer.
    Sato A; Kurihara M; Matsukawa M; Shimada K; Yamazaki T; Nakamachi M; Koda T
    Cancer Chemother Pharmacol; 2001 May; 47(5):380-4. PubMed ID: 11391851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Takifuji N; Nakagawa K; Tamanoi M; Nitta T; Hirashima T
    Br J Cancer; 1993 Oct; 68(4):777-82. PubMed ID: 8398707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.